A key opinion leader examines the overall survival data from the CheckMate 9LA study, which evaluated nivolumab plus ipilimumab plus chemotherapy in metastatic non-small cell lung cancer patients, and ...

Study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy vs. chemotherapy alone for the first-line treatment of advanced non-small cell lung cancer PRINCETON, ...

CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus chemotherapy over six years. The combination therapy was particularly ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the first presentation of results from the Phase 3 CheckMate -9LA trial, which demonstrated a statistically ...

Combination nivolumab (Opdivo) and ipilimumab (Yervoy) with chemotherapy offered a durable survival benefit versus chemotherapy alone in advanced non-small cell lung cancer (NSCLC) with brain ...

The Food and Drug Administration (FDA) has approved the combination of Opdivo (nivolumab; Bristol Myers Squibb) plus Yervoy (ipilimumab; Bristol Myers Squibb) and 2 cycles of platinum-doublet ...

Overall survival with circulating tumor DNA-guided therapy in advanced non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include ...

Bristol-Myers Squibb Company announced that CheckMate -9LA, a pivotal phase 3 trial evaluating Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) given concomitantly with two cycles of chemotherapy ...